

The Free Internet Journal for Organic Chemistry

Paper

Archive for Organic Chemistry

Arkivoc 2017, part iv, 121-136

Fused thieno[2,3-b]pyridines: synthesis and characterization of new condensed pyridothienopyrimidines

Etify A. Bakhite, Ahmed Abdou O. Abeed,* and Ola E. A. Ahmed

Department of Chemistry, Faculty of Science, University of Assiut, Assiut 71516, Egypt. E-mail: <u>ahmed.abdelrahman1@science.au.edu.eq</u>


Received 12-16-2016

Accepted 03-05-2017

Published on line 05-14-2017

Abstract

Reaction of cyanopyridine-2(1*H*)-thiones **2a,b** with chloroacetonitrile gave the corresponding 3aminothieno[2,3-*b*]pyridine-2-carbonitriles **4a,b**. Condensation of **4a,b** with triethyl orthoformate produced the methanimidate derivatives **6a,b** which upon treatment with hydrazine hydrate resulted in the formation of 3-amino-4-iminopyrido[3',2':4,5]thieno[3,2-*d*]pyrimidines **7a,b**. Aminothieno[2,3-*b*]pyridine-2-carboxamide **5** was prepared and reacted with triethyl orthoformate to give pyrimidine-4(3*H*)-one derivative **14**. Chlorination of **14** with phosphorus oxychloride gave 4-chloropyrimidine **15**, which in turn was reacted with hydrazine hydrate to produce 4-hydrazinopyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine **17**. Compounds **7a,b** and **17** were used as precursors for synthesizing other new pyridothienopyrimidines as well as triazolopyridothienopyrimidines, and pyridothienopyrimidotriazinoindoles. Structural formulas of all newly synthesized compounds were confirmed by elemental and spectral (IR, NMR, and mass) analyses.



Keywords: Thienopyridines, thienopyrimidines, pyridothienopyrimidines, triazolopyridothienopyrimidines, pyridothienopyrimidotriazinoindoles

Introduction


Many thieno[2,3-*b*]pyridines have been synthesized and investigated in relation to their biological and pharmacological importance.^{1,2} Some of them proved to possess antiviral, ^{3,4} anti-diabetic,⁵ antimicrobial,^{6,7} anti-inflammatory,⁸ antitumor,⁹ antiparasitic¹⁰ and neurotropic activities.¹¹ Also, thienopyrimidine derivatives have been the subject of several chemical and biological studies on account of their wide spectrum of biological activity.^{12,13} Furthermore, some pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidines are reported to exhibit antimicrobial,^{6,7} antiallergic,¹⁴ antiprotozoal¹⁵ and anti-anaphylactic activities.^{16,17} In view of the above observations and as a continuation of our previous work on pyridothienopyrimidines,¹⁸⁻²⁰ we describe herein the synthesis and characterization of the title compounds which are expected to be biologically active ones owing to the incorporation of different pharmacophores.

Results and Discussion

The broad synthetic utility reported for several 3-cyano-pyridine-2(1*H*)-thiones as starting materials of many heterocyclic systems, especially thieno[2,3-*b*]pyridines, prompted us to use 4-aryl-3-cyano-5-ethoxycarbonyl-6-methylpyridine-2(1*H*)-thiones **2a,b** as starting compounds in this investigation. These compounds **2a,b** were prepared by the reaction of arylidenecyanothioacetamides **1a,b** with ethyl acetoacetate in the presence of piperidine as a basic catalyst, according to the reported methods. ²¹ Reaction of 4-aryl-3-cyano-5-ethoxycarbonyl-6-methylpyridine-2(1*H*)-thiones **2a,b** with chloroacetonitrile, by refluxing in ethanol in the presence of sodium acetate, gave the corresponding 3-aminothieno[2,3-*b*]pyridine-2-carbonitriles **4a,b** rather than the expected 2-(cyanomethylthio) pyridines **3a,b**. The latter compounds **3a,b** were carefully obtained by reacting **2a,b** with chloroacetonitrile at room temperature. On heating compounds **3a,b** in ethanol containing sodium acetate, they underwent intramolecular Thorpe-Ziegler cyclization forming the corresponding thienopyridine-2-carboxamide **5** was prepared by reacting compounds **2a** with chloroacetamide in ethanol containing a slightly excess amount of sodium ethoxide according to our reported method ²¹ (Scheme 1).


The condensation of *o*-aminocarbonitriles **4a,b** with triethyl orthoformate by refluxing in acetic anhydride produced the methanimidate derivatives **6a,b**. Treatment of compounds **6a,b** with hydrazine hydrate in dioxane at room temperature resulted in the formation of ethyl 3-amino-9-aryl-3,4-dihydro-4-imino-7-methylpyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylates **7a,b** in good yields. Compounds **7a,b**, having the aminoimine structure, were utilized as new precursors for synthesizing novel fused heterocyclic compounds containing pyrido-thienopyrimidine moiety. Thus, refluxing compounds **7a,b** with an excess amount of triethyl orthoformate, under neat condition furnished ethyl 7-aryl-9-methyl[1,2,4]triazolo[2'',3''-c]-pyrido[3',2':4,5]thieno[2,3-*e*]pyrimidine-8-carboxylates **8a,b**. On the other hand, the 2-methyl analogs **9a,b** were prepared by reacting compounds **7a,b** with acetic anhydride at reflux temperature. Heating compounds **7a,b** with phenyl *iso*-thiocyanate in dry pyridine for a long time led to the formation of anilinotriazolopyridothienopyrimidines **10a,b**. When compounds **7a,b** were allowed to react with isatin, a cyclocondensation reaction occurred and the fused hexacyclic compounds **11a,b** were obtained in good yields (Scheme 2).

On treatment of compound **7a** with phenacyl bromide in boiling ethanol containing an equimolar amount of sodium acetate, the product was identified as 2H-pyrido[3'',2'':4',5']thieno[3',2':4,5]pyrimido[1,6-b][1,2,4]triazine **12** rather than the related isomer **13** (Scheme 3).



Scheme 1. Reagents and conditions: (i) Ethyl acetoaceate, piperidine, EtOH, 6 h; (ii) Chloroacetonitrile, AcONa, EtOH, stir. 3 h; (iii) Chloroacetonitrile, AcONa, EtOH, 3 h; (iv) Sodium acetate, EtOH, 3 h; (v) Chloroacetamide, EtONa, EtOH, 3 h.


This assignment based on the spectral data of this product. Thus, its IR spectrum revealed the absence of any band attributed to v NH and its ¹H NMR spectrum confirmed the presence of a characteristic signal corresponding to CH_2 group in the triazine ring. Refluxing *o*-aminocarboxamide **5** with triethyl orthoformate in acetic anhydride led to the formation of ethyl 9-(4-methoxyhenyl)-7-methyl-4-oxo-3,4-dihydropyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylate **14**.



Scheme 2. Reagents and conditions: (i) Triethyl orthoformate, Ac₂O, 2 h; (ii) Hydrazine hydrate, dioxane, stir. 4 h; (iii) Triethyl orthoformate, 3 h; (iv) Acetic anhydride, 2 h; (v) Phenyl *iso*-thiocyanate, steam bath 8 h; (vi) Isatin, EtOH, 3 h.


Chlorination of **14**, by heating with an excess amount of phosphorus oxychloride, produced ethyl 4-chloro-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylate (**15**) in a good yield. The latter compound underwent a nucleophilic substitution reaction upon treatment with thiourea to give pyrimidine-2(1*H*)-thione **16**. Also, the reaction of **15** with hydrazine hydrate gave 4-hydrazinopyrimidine derivative **17** (Scheme 4).

The compound 17 was also served as a facile point to departure to other pyridothieno-pyrimidine derivatives. Thus, condensation with 4-chlorobenzaldehyde gave 4-(4-chlorobenzylidene) its hydrazinopyrimidine derivative 18. Similarly, the hydrazone 19 was obtained by reacting compound 17 with acetophenone (Scheme 7). Heating compound 17 with acetylacetone at reflux temperature produced the dimethylpyrazole derivative 20. Treatment of compound 17 with ethyl (ethoxymethylene)cyanoacetate led to the formation of ethyl 4-(3'-amino-4'-ethoxycarbonylpyrazol-2'-yl)-7-methyl-9-(4-methoxyphenyl)pyrido[3',2':4,5]thieno[3,2-d]-pyrimidine-8-carboxylate (21) (Scheme 5).




Scheme 3. Reagent and condition: (i) Phenacyl bromide, AcONa, EtOH, 3 h.


Heating hydrazino compound **17** in formic acid for a long time resulted in the formation of triazolo derivative **8a** rather than the expected isomer **23** (Scheme 6). From the thermodynamic point of view, ²² the compound **8**a seems to be more stable than the corresponding isomer **23**. The pathway of the latter reaction may be involving firstly the usual formation of compound **23** *via* the intermediacy of acid hydrazide **22**. Under the applied reaction conditions, ²² compound **23** underwent spontaneously *Dimroth in situ* to give the most stable isomer **8a**. The triazole intermediate **23** was successfully prepared by heating hydrazino compound **17** with triethyl orthoformate, under the neat condition, at reflux temperature (Scheme 6). Beside elemental and spectral analyses, the above structure **8a** was further confirmed by comparison with authentic sample (m. p., mixed mp and TLC) previously prepared in this paper.




Scheme 4. Reagents and conditions: (i) Triethyl orthoformate, Ac₂O, 4 h; (ii) Phosphorus oxychloride, dioxane, steam bath 3 h; (iii) Thiourea, EtOH, 6 h; (iv) Hydrazine hydrate, EtOH, 2 h.



Scheme 5. Reagents and conditions: (i) 4-Chlorobenzaldehyde, AcOH, EtOH, 4 h; (ii) Acetophenone, AcOH, EtOH, 4 h; (iii) Acetyl acetone, 4 h; (iv) Ethyl (ethoxymethylene) cyanoacetate, EtOH, 4 h.



Scheme 6. Reagents and conditions: (i) Formic acid, 3 h; (ii) Triethyl orthoformate, 4 h.



Scheme 7. The mechanism of the Dimroth rearrangement for triazole derivative 23.

The mechanism of the Dimroth rearrangement 23 under investigation is given in scheme 7. This rearrangement is promoted here by aqueous acid (Formic acid 85%). It involves initially covalent hydration of **23**. The hydroxy group enters position 5, then the pyrimidine ring opens and forms the carbonyl intermediate A; the CO group then attacks the most nucleophilic *N*-2 of the triazole ring and cyclizes to give the rearranged triazolopyrimidine **8a**.

Experimental Section

General. Starting materials were obtained from commercial suppliers and used without further purification. All melting points were determined on a Gallenkamp apparatus and are uncorrected. The IR spectra were recorded on a Shimadzu 470 IR-spectrophotometer (KBr; v_{max} in cm⁻¹). The NMR spectra were taken on a Varian EM-390, 90 MHz spectrometer or on a JEOL LA 400 MHz FT-NMR spectrometer using TMS as an internal standard. Chemical shifts are given in δ ppm and coupling constant (*J*) is given in Hz. Electron impact (EI) MS spectra were carried out on a JEOL JMS-600 spectrometer. Elemental analyses (C, H, N and S) were performed on an Elemental Analyses system GmbH vario EL V2.3 1998 CHNS Mode (Assiut University). The reactions were monitored by TLC.

4-Aryl-3-cyano-5-ethoxycarbonyl-6-methylpyridine-2(1*H***)-thiones (2a,b).** These compounds were prepared according to the reported method.²¹

4-Aryl-3-cyano-2-cyanomethylthio-5-ethoxycarbonyl-6-methylpyridines (3a,b). To a suspension of compound **2a,b** (10 mmol) and sodium acetate trihydrate (1.36 g, 10 mmol) in ethanol (40. mL), chloroacetonitrile (0.64 mL, 10 mmol) was added. The resulting mixture was stirred at room temperature for 3 h. The white precipitate that formed was collected and recrystallized from ethanol to give **4a,b**.

3-Cyano-2-cyanomethylthio-5-ethoxycarbonyl-4-(4-methoxyphenyl)-6-methylpyridine (3a). Prepared as white needles in 92% yield; mp 121-122 °C. IR (KBr) cm⁻¹: 2250 (C=N, non conjugated), 2220 (C=N, conjugated), 1731 (C=O); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.30-7.32 (dd, *J* 2.3 Hz, 2H, Ar-H), 6.97-7.00 (dd, *J* 2.3 Hz, 2H, Ar-H), 4.05-4.11 (q, *J* 7.0 Hz, 2H, OCH₂), 4.07 (s, 2H, SCH₂), 3.85 (s, 3H, OCH₃), 2.67 (s, 3H, CH₃), 0.98-1.02 (t, *J* 7.0 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ ppm: 166.6, 161.0, 159.2, 158.8, 152.6, 129.7, 126.7, 126.2, 115.8, 114.3, 114.1, 105.1, 61.9, 55.4, 23.4, 15.9, 13.7; MS: *m/z* 367 (M⁺, 100%), 352 (M⁺-CH₃, 12%), 337 (M⁺-2CH₃, 25%), 322 (M⁺- OC₂H₅, 14%). Anal. Calcd. for C₁₉H₁₇N₃O₃S (367.1)): C, 62.11; H, 4.66; N, 11.44; S, 8.73%. Found: C, 62.43; H, 4.49; N, 11.90; S, 8.92%.

(4-Chlorophenyl)-3-cyano-2-cyanomethylthio-5-ethoxycarbonyl-6-methylpyridine (**3b**). Prepared as white needles in 90% yield; mp 97-99 °C. IR (KBr) cm⁻¹: 2248 (C≡N, none conjugated), 2217 (C≡N, conjugated), 1735 (C=O); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.46-7.49 (dd, *J* 2.3 Hz, 2H, Ar-H), 7.29-7.32 (dd, *J* 2.3 Hz, 2H, Ar-H), 4.05-4.10 (m, 4H, SCH₂ and OCH₂), 2.70 (s, 3H, CH₃), 0.98-1.01 (t, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ 166.0, 159.7, 159.1, 151.6, 136.5, 132.5, 129.5, 129.1, 126.4, 115.7, 113.6, 104.9, 62.1, 23.5, 16.0, 13.6. MS: *m/z* 371 (M⁺, 100%), 373 (M⁺+2, 42%), 343 (24%), 336 (10%), 326 (M⁺- OC₂H₅, 15%). Anal. Calcd. for C₁₈H₁₄ClN₃O₂S (371.1): C, 58.14; H, 3.79; N, 11.30; S, 8.62%. Found: C, 58.46; H, 3.72; N, 11.65; S, 8.27%.

3-Amino-4-aryl-5-ethoxycarbonyl-6-methylthieno[2,3-b]pyridine-2-carbonitriles (4a,b).

Method (A) To a mixture of compound **2a,b** (10 mmol) and sodium acetate trihydrate (1.50 g, 11 mmol) in ethanol (40 mL), chloroacetonitrile (0.64 mL, 10 mmol) was added. The resulting mixture was heated under reflux for 3 h. The precipitate that formed on cooling was collected and recrystallized from ethanol to afford **4a,b**.

3-Amino-5-ethoxycarbonyl-4-(4-methoxyphenyl)-6-methylthieno[2,3-*b***]pyridine-2-carbonitrile** (4a). Prepared as yellow needles in 90% yield; mp 184-185 °C. IR (KBr) cm⁻¹: 3476, 3342 (NH₂); 2976 (C-H, aliphatic); 2199 (C=N); 1729 (C=O); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.27-7.30 (dd, *J* 2.4 Hz, 2H, Ar-H), 7.00-7.03 (dd, *J* 2.4 Hz, 2H, Ar-H), 4.32 (s, 2H, NH₂), 4.01-4.06 (q, *J* 7.0 Hz, 2H, OCH₂), 3.88 (s, 3H, OCH₃), 2.67 (s, 3H, CH₃), 0.99-

1.03 (t, *J* 7.2 Hz, 3H, CH₃ of ester); ¹³C NMR and Dept 135 (100 MHz, CDCl₃) δ ppm: 167.5, 161.3, 160.6, 156.3, 149.3, 143.8, 130.0 (CH), 127.6, 125.4, 118.5, 114.7, 114.1 (CH), 61.6 (OCH₂), 55.4 (OCH₃), 23.1 (CH₃ at C-6), 13.8 (CH₃ of ester group). MS: *m/z* 367 (M⁺, 100%), 339 (M⁺-CO, 10%), 322 (M⁺-OEt, 15%), 321 (M⁺- EtOH, 15%). Anal. Calcd. for C₁₉H₁₇N₃O₃S (367.1): C, 62.11; H, 4.66; N, 11.44; S, 8.73%. Found: C, 62.00; H, 4.70; N, 11.83; S, 9.02%.

3-Amino-4-(4-chlorophenyl)-5-ethoxycarbonyl-6-methylthieno[2,3-*b***]pyridine-2-carbonitrile (4b). Prepared as yellow needles in 93% yield; mp 175-176 °C. IR (KBr) cm⁻¹: 3484, 3343, 3228 (NH₂), 2977 (C-H aliphatic), 2200 (C=N), 1727 (C=O); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.49-7.52 (dd,** *J* **2.4 Hz, 2H, Ar-H), 7.31-7.34 ((dd,** *J* **2.4 Hz, 2H, Ar-H), 4.23 (s, 2H, NH₂), 4.03-4.09 (q,** *J* **7.4 Hz, 2H, OCH₂), 2.69 (s, 3H, CH₃), 1.00-1.03 (t,** *J* **7.2 Hz, 3H, CH₃); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 167.1, 161.4, 156.5, 148.7, 142.5, 136.1, 132.0, 130.1 (CH), 129.0 (CH), 127.1, 118.0, 114.5, 61.8 (OCH₂), 23.2 (CH₃ at C-6), 13.7 (CH₃ of ester group); MS:** *m/z* **371 (M⁺, 100%), 373 (M⁺+2, 39%), 343 (M⁺- CO, 21%) and 326 (M⁺- OEt, 12%). Anal. Calcd. for C₁₈H₁₄ClN₃O₂S (371.1): C, 58.14; H, 3.79; N, 11.30; S, 8.62%. Found: C, 58.23; H, 3.70; N, 11.48; S, 8.72%.**

Method (B). A suspension of compound **3a,b** (10 mmol) and sodium acetate trihydrate (0.14 g, 1 mmol) in ethanol (30 mL) was heated at reflux for 3 h. The crystalline product that formed on cooling was collected and recrystallized from ethanol in the form of yellow needles of **4a,b**. These products are identical with those reported in method A in all aspects (yield: 83-88%).

3-Amino-5-ethoxycarbonyl-4-(4-methoxyphenyl)-6-methylthieno[2,3-*b***]pyridine-2-carboxamide** (5). This compound was prepared according to the reported method.²¹

Ethyl *N*-{4-aryl-2-cyano-5-ethoxycarbonyl-6-methylthieno[2,3-*b*]pyridin-3-yl}-methanimidates (6a,b). A mixture of compound 4a,b (10 mmol), triethyl orthoformate (5 mL) in acetic anhydride (15 mL) was heated under reflux for 2 h and then allowed to cool. The solid that formed was collected and recrystallized from ethanol to afford 6a,b.

Ethyl N-{2-cyano-5-ethoxycarbonyl-4-(4-methoxyphenyl)-6-methylthieno[2,3-*b***]pyridin-3-yl}-methanimidate (6a). Prepared as white needles in 90% yield; mp 154-155 °C. IR (KBr) cm⁻¹: 2974, 2836 (C-H aliphatic), 2212 (C=N), 1731 (C=O), 1632 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.54 (s, 1H, N=CH), 7.10-7.12 (d,** *J* **8.4 Hz, 2H, Ar-H), 6.89-6.92 (d,** *J* **8.8 Hz, 2H, Ar-H), 4.03-4.08 (q,** *J* **7.2 Hz, 2H, OCH₂ of ester group), 3.84 (s, 3H, OCH₃), 3.60-3.65 (q,** *J* **6.8 Hz, 2H, OCH₂ of ethoxygroup), 2.69 (s, 3H, CH₃ at C-6), 1.12-1.16 (t,** *J* **7.2 Hz, 3H, CH₃ of ethoxygroup), 0.98-1.01 (t,** *J* **7.0 Hz, 3H, CH₃ of ester group); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃): δ 167.7, 160.7, 159.9, 156.5 (N=CH), 156.3, 151.2, 145.0, 130.5 (CH), 128.5, 126.8, 122.5, 114.1, 114.0, 112.9 (CH), 91.9, 62.9 (OCH₂), 61.6 (OCH₂), 55.3 (OCH₃), 23.1 (CH₃ at C-6), 13.7 (CH₃ of ester group), 13.6 (CH₃ of ethoxy group); MS:** *m/z* **423 (M⁺, 100%), 378 (M⁺- OEt, 13%), 367 (46%) and 132 (13%). Anal. Calcd. for C₂₂H₂₁N₃O₄S (423.1): C, 62.40; H, 5.00; N, 9.92; S, 7.57%. Found: C, 62.17; H, 4.79; N, 9.57; S, 7.82%.**

Ethyl *N*-{4-(4'-chlorophenyl)-2-cyano-5-ethoxycarbonyl-6-methylthieno[2,3-b]pyridin-3-yl}-methanimidate (6b). Obtained as white needles in 92% yield; mp 146-147 °C. IR (KBr) cm⁻¹: 2981 (C-H aliphatic), 2213 (C=N), 1727 (C=O), 1634 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.59 (s, 1H, N=CH), 7.37-7.39 (dd, *J* 2.0 Hz, 2H, Ar-H), 7.14-7.16 (dd, *J*=2.0 Hz, 2H, Ar-H), 4.03-4.09(q, *J* 8.0 Hz, 2H, OCH₂ of ester), 3.56-3.62 (q, *J* 7.0 Hz, 2H, OCH₂ of ethoxy group), 2.70 (s, 3H, CH₃), 1.17 -1.20 (t, *J* 7.0 Hz, 3H, CH₃ of ethoxygroup), 0.98-1.02 (t, *J* 7.2 Hz, 3H, CH₃ of ester group); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 167.2, 160.7, 156.8, 156.5 (N=CH), 150.8, 143.8, 134.7, 133.2, 130.6 (CH), 128.0, 127.7 (CH), 122.1, 113.8, 92.1, 63.2 (OCH₂), 61.7 (OCH₂), 23.2 (CH₃ at C-6), 13.7 (CH₃ of ester group), 13.7 (CH₃ of ethoxy group); MS: *m/z* 427 (M⁺, 100%), 429 (M⁺+2, 41%), 382 (M⁺-OEt, 14%), 371 (60%), 343 (21%). Anal. Calcd. for C₂₁H₁₈ClN₃O₃S (427.1): C, 58.95; H, 4.24; N, 9.82; S, 7.49%. Found: C, 58.82; H, 4.31; N, 9.67; S, 7.72%.

Ethyl 3-amino-9-aryl-3,4-dihydro-4-imino-7-methylpyrido[3',2':4,5]thieno[3,2-d]pyrimidine-8-carboxylates (7a,b). To a suspension of compound **6a,b** (5 mmol) in dioxane (20 mL), hydrazine hydrate 99% (2 mL) was added. The reaction mixture was stirred at room temperature for 4 h. The solid that formed was collected and recrystallized from ethanol to give **7a,b**.

Ethyl 3-amino-3,4-dihydro-4-imino-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-*d***]pyrimidine-8-carboxylate (7a)**. Obtained as white needles in 78% yield; mp 204-206 °C. IR (KBr) cm⁻¹: 3306, 3157 (NH, NH₂), 2979 (C-H aliphatic), 1707 (C=O), 1609 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.89 (s, 1H, CH pyrimidine), 7.27-7.29 (d, *J* 8.8 Hz, 2H, Ar-H), 6.93-6.95 (d, *J* 8.8 Hz, 2H, Ar-H), 4.77 (s, 2H, NH₂), 4.05-4.08 (q, *J* 7.0 Hz, 2H, OCH₂), 3.87 (s, 3H, OCH₃), 2.71 (s, 3H, CH₃), 1.00 -1.04 (t, *J* 7.0 Hz, 3H, CH₃ of ester); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 168.3, 161.9, 159.8, 155.4, 154.4, 148.2 (CH pyrimidine), 145.9, 145.9, 130.7 (CH), 128.6, 126.9, 124.0, 121.4, 112.9 (CH), 61.5 (OCH₂), 55.2 (OCH₃), 23.1 (CH₃ at C-6), 13.8 (CH₃ of ester group); MS: *m/z* 409 (M⁺, 100%), 393 (M⁺- NH₂, 19%); 367 (17%) and 365 (10%). Anal. Calcd. for C₂₀H₁₉N₅O₃S (409.1): C, 58.67; H, 4.68; N, 17.10; S, 7.83%. Found: C, 58.44; H, 4.70; N, 17.36; S, 7.61%.

Ethyl 3-amino-9-(4-chlorophenyl)-3,4-dihydro-4-imino-7-methylpyrido[3',2':4,5]thieno [3,2-*d***]pyrimidine-8carboxylate (7b). Obtained as white needles in 85% yield; mp 208-209 °C. IR (KBr) cm⁻¹: 3309, 3161 (NH, NH₂), 2986 (CH aliphatic), 1708 (C=O), 1613 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.87 (s, 1H, CH pyrimidine), 7.38-7.40 (dd,** *J* **2.4 Hz, 2H, Ar-H), 7.27-7.29 (dd,** *J* **2.4 Hz, 2H, Ar-H), 4.78 (s, 2H, NH₂), 4.05-4.10 (q,** *J* **7.0 Hz, 2H, OCH₂), 2.72 (s, 3H, CH₃), 1.00 -1.03 (t,** *J* **7.2 Hz, 3H, CH₃ ester); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 167.8, 161.9, 155.7, 154.3, 148.3 (CH pyrimidine), 145.6, 144.6, 134.6, 133.1, 130.7 (CH), 128.0, 127.7 (CH), 123.7, 121.6, 61.7 (OCH₂), 23.2 (CH₃ at C-6), 13.7 (CH₃ ester); MS:** *m/z* **413 (M⁺, 100%), 415 (M⁺+2, 41%), 397 (M⁺- NH₂, 13%), 371 (16%). Anal. Calcd. for C₁₉H₁₆ClN₅O₂S (413.1): C, 55.14; H, 3.90; N, 16.92; S, 7.75%. Found: C, 55.09; H, 4.11; N, 16.78; S, 8.00%.**

General procedures for the synthesis of ethyl 7-aryl-9-methyl[1,2,4]triazolo[2",3"-c] pyrido[3',2':4,5]thieno[2,3-e]pyrimidine-8-carboxylates (8a,b)

Method (A). Compound **7a,b** (2 mmol) in triethyl orthoformate (10 mL) was heated at reflux for 3 h. The precipitate that formed while hot was collected and recrystallized from ethanol to afford **8a,b**.

Ethyl 7-(4-methoxyphenyl)-9-methyl[1,2,4]triazolo[2'',3''-c]pyrido[3',2':4,5]thieno[2,3-*e***]pyrimidine-8carboxylate (8a). Obtained as white fine needles in 76% yield; mp 205-206 °C. IR (KBr) cm⁻¹: 1726 (C=O); ¹H NMR (400 MHz, CDCl₃) δ ppm: 9.11 (s, 1H, CH pyrimidine), 8.46 (s, 1H, CH triazole), 7.34-7.36 (d, 2H, Ar-H), 6.99-7.02 (dd, 2H, Ar-H), 4.10-4.14 (q, 2H, OCH₂), 3.91 (s, 3H, OCH₃), 2.77 (s, 3H, CH₃), 1.03-1.05 (t, 3H, CH₃ ester); MS:** *m/z* **419 (M⁺, 100%), 387 (20%); 347 (11%). Anal. Calcd. for C₂₁H₁₇N₅O₃S (419.1): C, 60.13; H, 4.09; N, 16.70; S, 7.64%. Found: C, 60.08; H, 4.11; N, 16.56; S, 7.39%.**

Ethyl 7-(4-chlorophenyl)-9-methyl[1,2,4]triazolo[2'',3''-c]pyrido[3',2':4,5]thieno[2,3-e]pyrimidine-8carboxylate (8b). Obtained as white fine needles in 80% yield; mp 244-245 °C. IR (KBr) cm⁻¹: 2979 (C-H, aliphatic), 1727 (C=O), 1623 cm⁻¹ (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.98 (s, 1H, CH pyrimidine), 8.47 (s, 1H, CH triazole), 7.45-7.47 (d, 2H, Ar-H), 7.34-7.36 (d, 2H, Ar-H), 4.08-4.14 (q, 2H, OCH₂), 2.78 (s, 3H, CH₃), 1.03-1.06 (t, 3H, CH₃ ester); MS: *m/z* 423 (M⁺, 100%), 425 (M⁺+2, 40%). Anal. Calcd. for C₂₀H₁₄ClN₅O₂S (423.1): C, 56.67; H, 3.33; N, 16.52; S, 7.56%. Found: C, 56.80; H, 3.31; N, 16.77; S, 7.34%.

Method (B). Compound **17** (1.64 g; 4 mmol) in formic acid 85% (20 mL) was heated at reflux for 6 h. The precipitate that formed on cooling was collected by filtration and recrystallized from ethanol in the form of white needles of compound **8a** (yield: 67%). This product is identical to that reported above in all aspects.

Ethyl 7-aryl-2,9-dimethyl[1,2,4]triazolo[2'',3''-c]pyrido[3',2':4,5]thieno[2,3-e]pyrimidine-8-carboxylates (9a,b). Compound **7a,b** (2 mmol) in acetic anhydride (10 mL) was heated under reflux for 2 h. The crystalline precipitate that formed while hot was collected by filtration and recrystallized from ethanol to give **9a,b**.

Ethyl 2,9-dimethyl-7-(4-methoxyphenyl)[1,2,4]triazolo[2",3"-c]pyrido[3',2':4,5]thieno[2,3-e]pyrimidine-8carboxylate (9a). Obtained as white crystals in 88% yield; mp 220-221°C. IR (KBr) cm⁻¹: 2964 (C-H aliphatic), 1736 (C=O), 1612 (C=N). ¹H NMR (400 MHz, CDCl₃): δ 7.99 (s, 1H, CH pyrimidine), 7.34-7.36 (dd, *J* 1.8 Hz, 2H, Ar-H), 6.99-7.01 (dd, *J* 1.8 Hz, 2H, Ar-H), 4.08-4.14 (q, *J* 7.0 Hz, 2H, OCH₂), 3.91 (s, 3H, OCH₃), 2.77 (s, 3H, CH₃), 2.67 (s, 3H, CH₃ triazole), 1.03-1.06 (t, *J* 7.0 Hz, 3H, CH₃ of ester); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 168.1, 165.9, 162.1, 160.0, 156.0, 148.8, 145.5, 144.5, 136.6 (CH pyrimidine), 130.5 (CH), 128.9, 126.9, 122.9, 119.2, 113.2 (CH), 61.6 (OCH₂), 55.3 (OCH₃), 23.2 (CH₃ pyridine), 14.5 (CH₃ triazole), 13.8 (CH₃ ester); MS: *m/z* 433 (M⁺, 100%), 404 (M⁺- Et, 25%); 388 (M⁺- EtO, 30%) and 360 (M⁺- CO₂Et, 35%). Anal. Calcd. for C₂₂H₁₉N₅O₃S (433.1): C, 60.96; H, 4.42; N, 16.16; S, 7.40%. Found: C, 61.13; H, 4.41; N, 16.00; S, 7.18%.

Ethyl 7-(4-chlorophenyl)-2,9-dimethyl[1,2,4]triazolo[2",3"-c]pyrido[3',2':4,5]thieno[2,3-e]pyrimidine-8carboxylate (9b). Obtained as white crystals in 85% yield; mp 245-247 °C. IR (KBr) cm⁻¹: 2979 (C-H aliphatic), 1727 (C=O), 1623 (C=N). ¹H NMR (400 MHz, CDCl₃): δ 8.980 (s, 1H, CH pyrimidine), 7.455-7.471 (dd, *J* 2.0 Hz, 2H, Ar-H), 7.340-7.361 (dd, *J* 2.0 Hz, 2H, Ar-H), 4.087-4.141(q, *J* 7.2 Hz, 2H, OCH₂), 2.787 (s, 3H, CH₃), 2.682 (s, 3H, CH₃ attached to triazole ring), 1.030 -1.065 (t, *J* 7.0 Hz, 3H, CH₃ of ester); ¹³C NMR and DEPT 135 (100 MHz, CDCl₃) δ ppm: 167.69, 166.02, 162.20, 156.30, 148.75, 144.28, 144.16, 136.76 (CH pyrimidine), 134.89, 133.20, 130.58 (CH), 128.45, 128.07(CH), 122.56, 119.52, 61.84 (OCH₂), 23.29 (CH₃ attached to pyridine ring), 14.57(CH₃ attached to triazole ring), 1.373 (CH₃ of ester group); MS: *m/z* 437 (M⁺, 100%), 439 (M⁺+2, 41), 408 (M⁺-Et, 25%), 392 (M⁺-OC₂H₅, 41), 365 (M⁺- CO₂Et, 22%) and 356 (13%). Anal. Calcd. for C₂₁H₁₆ClN₅O₂S (437.1): C, 57.60; H, 3.68; N, 15.99; S, 7.32%. Found: C, 57.23; H, 3.70; N, 15.70; S, 7.54%.

Ethyl 2-anilino-7-aryl-9-methyl[1,2,4]triazolo[2",3"-*c*]pyrido[3',2':4,5]thieno[2,3-*e*]pyrimidine-8carboxylates (10a,b). To a solution of compound 7a,b (5 mmol) in pyridine (10 mL), phenyl isothiocyanate (0.65 mL, 5 mmol) was added. The reaction mixture was heated on a steam bath for 8 h and then allowed to stand at room temperature overnight. The precipitate that formed was collected and recrystallized from DMF-H₂O mixture to afford 10a,b.

Ethyl 2-anilino-7-(4-methoxyphenyl)-9-methyl[1,2,4]triazolo[2",3"-*c***]pyrido[3',2':4,5]thieno[2,3***e***]pyrimidine-8-carboxylate (10a). Prepared as pale yellow crystals in 73% yield; Yield: 73%; mp 285-286 °C. IR (KBr) cm⁻¹: 3500 (NH), 2976 (C-H aliphatic), 1720 (C=O). ¹H NMR (400 MHz, CDCl₃) δ ppm: 6.92-7.83 (m, 11H, CH pyrimidine, NH and Ar-H), 4.02 (q, 2H, OCH₂), 3.77 (s, 3H, OCH₃), 2.68 (s, 3H, CH₃), 0.97 (t, 3H, CH₃ of ester); MS:** *m/z* **510 (M⁺, 3%), 393 (M⁺-PhNCN, 100%), 365 (42%), 349 (13%), 321 (18%). Anal. Calcd. for C₂₇H₂₂N₆O₃S (510.1): C, 63.52; H, 4.34; N, 16.46; S, 6.28%. Found: C, 63.34; H, 4.11; N, 16.43; S, 6.30%.**

Ethyl 2-anilino-7-(4-chlorophenyl)-9-methyl[1,2,4]triazolo[2'',3''-*c***]pyrido[3',2':4,5]thieno[2,3-***e***]pyrimidine-8-carboxylate (10b).** Prepared as pale yellow crystals in 78% yield; mp 300-302 °C. IR (KBr) cm⁻¹: 3500 (NH), 1725 (C=O), 1644 (C=N). ¹H NMR (90 MHz, CF₃CO₂D) δ ppm: 8.10 (s, 1H, CH pyrimidine), 7.10-7.70 (m, 9H, Ar-H), 4.00-4.40 (q, 2H, OCH₂), 2.80 (s, 3H, CH₃), 1.00-1.30 (t, 3H, CH₃ of ester); MS: *m/z* 514 (M⁺, 10%), 397 (M⁺-PhNCN, 100%), 369 (58%), 353 (20%), 325 (27%). Anal. Calcd. for C₂₆H₁₉ClN₆O₂S (514.1): C, 60.64; H, 3.72; N, 16.32; S, 6.23%. Found: C, 60.59; H, 3.83; N, 16.16; S, 6.11%.

Condensation of compounds 8a,b with isatin; formation of fused hexacyclic compounds 11a,b. A mixture of compound **7a,b** (2 mmol) and isatin (0.30 g, 2 mmol) in ethanol (20 mL) was heated under reflux for 3 h. The precipitate that formed while hot collected and recrystallized from dioxane to give **11a,b**.

3-Ethoxycarbonyl-4-(4-methoxyphenyl)-2-methylpyrido[3",2":4",5"]thieno[3",2":4',5']-

pyrimido[1',6':2,3][1,2,4]triazino[5,6-*b*]indole (11a). Prepared as red crystals in 82% yield; mp 334-335 °C. IR (KBr) cm⁻¹: 2947 (CH aliphatic), 1727 (C=O), 1634 (C=N); MS: *m/z* 520 (M⁺, 100%), 519 (M⁺-H, 29%), 491(M⁺-Et, 26%). Anal. Calcd. for C₂₈H₂₀N₆O₃S (520.1): C, 64.60; H, 3.87; N, 16.14; S, 6.16%. Found: C, 64.51; H, 3.91; N, 16.00; S, 6.18%.

4-(4-Chlorophenyl)-3-ethoxycarbonyl-2-methylpyrido[3"',2":4",5"]thieno[3",2":4',5']-

pyrimido[1',6':2,3][1,2,4]triazino[5,6-*b***]indole (11b).** Prepared as red crystals in 81% yield; mp 342-343 °C. IR (KBr) cm⁻¹: 1727 (C=O), 1631 (C=N). ¹H NMR (90 MHz, CF₃CO₂D) δ ppm: 9.70 (s, 1H, CH pyrimidine), 7.40-8.70 (m, 8H, Ar-H), 4.20-4.60 (q, 2H, OCH₂), 3.20 (s, 3H, CH₃), 1.00-1.30 (t, 3H, CH₃ of ester); MS: *m/z* 524 (M⁺, 100%), 526 (M⁺+2, 40%), 495 (M⁺-Et, 28%), 451 (M⁺-CO₂Et, 14%). Anal. Calcd. for C₂₇H₁₇ClN₆O₂S (524.1): C, 61.77; H, 3.26; N, 16.01; S, 6.11%. Found: C, 61.40; H, 3.23; N, 15.89; S, 6.07%.

Ethyl 8-(4-methoxyphenyl)-10-methyl-3-phenyl-2*H*-pyrido[3",2":4',5']thieno[3',2':4,5]-pyrimido[1,6*b*][1,2,4]triazine-9-carboxylate (12). To a mixture of compound 7a (0.82 g, 2 mmol) and phenacyl bromide (0.40 g; 2 mmol) in ethanol (20 mL), anhydrous sodium acetate (0.33 g; 4 mmol) was added. The reaction mixture was heated under reflux for 3 h. The precipitate that formed while hot was filtered, washed with water and recrystallized from ethanol to afford 12. Obtained as pale yellow needles in 81% yield; mp 237-238 °C. IR (KBr) cm⁻¹: 2836 (C-H, aliphatic), 1716 (C=O), 1671 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.80 (s, 1H, CH pyrimidine), 6.88-7.73 (m, 9H, Ar-H), 4.76 (s, 2H, CH₂ triazine), 4.01-4.02 (q, 2H, OCH₂), 3.81 (s, 3H, OCH₃), 2.64 (s, 3H, CH₃), 0.97 (s, 3H, CH₃); MS: *m/z* 509 (M⁺, 100%), 405 (M⁺-PhCN, 23%), 377 (17%). Anal. Calcd. for C₂₈H₂₃N₅O₃S (509.1): C, 66.00; H, 4.55; N, 13.74; S, 6.29%. Found: C, 65.87; H, 4.41; N, 13.80; S, 6.40%.

Ethyl 9-(4-methoxyphenyl)-7-methyl-4-oxo-3,4-dihydropyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8carboxylate (14). A mixture of compound 5 (1.92 g, 5 mmol) and triethyl orthoformate (5 mL) in acetic anhydride (15 mL) was heated under reflux for 4 h. The precipitate that formed while hot was collected by filtration, washed with ethanol and crystallized from DMF to give 15. Obtained as white needles in 80% yield; mp 298-299 °C. IR (KBr) cm⁻¹: 3220 (NH), 1731 (C=O, ester), 1659 (C=O, pyrimidinone); ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 12.75 (s, 1H, NH), 8.03 (s, 1H, CH pyrimidinone), 7.26-7.28 (s, *J* 8.0 Hz, 2H, Ar-H), 6.98-7.00 (d, *J* 8.0 Hz, 2H, Ar-H), 4.06-4.08 (q, 2H, OCH₂), 3.83 (s, 3H, OCH₃), 2.64 (s, 3H, CH₃ at C-7), 0.95-0.97 (t, 3H, CH₃ ester); MS: *m*/*z* 395 (M⁺, 100%), 366 (M⁺- Et, 28%), 350 (M⁺-OC₂H₅, 36%), 322 (M⁺- CO₂Et, 22%). Anal. Calcd. for C₂₀H₁₇N₃O₄S (395.1): C, 60.75; H, 4.33; N, 10.63; S, 8.11%. Found: C, 60.66; H, 4.41; N, 10.86; S, 7.85%.

Ethyl 4-chloro-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-*d***]pyrimidine-8-carboxylate (15).** A suspension of compound **14** (1.97 g, 5 mmol) in an excess amount of phosphorus oxychloride (25 mL) was heated under reflux on a steam bath for 3 h. The reaction mixture was cooled and then poured with vigorous stirring into ice-cooled water (150 mL). The solid that separated was filtered and crystallized from ethanol to afford **15**. Obtained as white pale yellow crystals in 79% yield; mp 166-167°C. IR (KBr) cm⁻¹: 2936 (C-H aliphatic), 1732 (C=O), 1608 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.81 (s, 1H, CH pyrimidine), 7.31-7.34 (dd, *J* 2.4 Hz, 2H, Ar-H), 6.99-7.01 (dd, *J* 2.4 Hz, 2H, Ar-H), 4.08-4.14 (q, *J* 7.0 Hz, 2H, OCH₂), 3.90 (s, 3H, OCH₃), 2.77 (s, 3H, CH₃), 1.02-1.06 (t, *J* 7.2 Hz, 3H, CH₃ ester). Anal. Calcd. for C₂₀H₁₆ClN₃O₃S (413.1): C, 58.04; H, 3.90; N, 10.15; S, 7.75; Cl, 8.57%. Found: C, 57.87; H, 4.11; N, 10.14; S, 8.13; Cl, 8.40%.

Ethyl 9-(4-chlorophenyl)-8-ethoxycarbonyl-7-methyl-4-thioxo-3,4-dihydro-pyrido[3',2':4, 5]thieno[3,2*d*]pyrimidine-8-carboxylate (16). A mixture of 4-chloro compound 15 (2.07 g; 5 mmol) and thiourea (0.76 g; 10 mmol) in ethanol (30 mL) was heated under reflux for 6 h and then allowed to cool. The precipitated solid was collected, dissolved in sodium hydroxide solution 8% (20 mL) and filtered. The clear filtrate was acidified with acetic acid whereby a yellow product precipitated. It was collected by filtration and crystallized from acetic acid to afford **16**. Obtained as yellow crystals in 80% yield; mp 276-277 °C. IR (KBr) cm⁻¹: 3150 (NH aliphatic), 1730 (C=O, ester); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.38 (s, 1H, CH pyrimidine), 7.34-7.36 (dd, *J* 2.2 Hz, 2H, Ar-H), 6.97-6.99 (dd, *J* 2.0 Hz, 2H, Ar-H), 6.65 (s, 1H, NH), 4.06-4.11 (q, *J* 7.2 Hz, 2H, OCH₂), 3.89 (s, 3H, OCH₃), 2.74 (s, 3H, CH₃), 1.01-1.05 (t, *J* 7.2 Hz, 3H, CH₃ ester). Anal. Calcd. for C₂₀H₁₇N₃O₃S₂ (411.1): C, 58.38; H, 4.16; N, 10.21; S, 15.58%. Found: C, 58.17; H, 4.30; N, 10.08; S, 15.29%.

Ethyl 4-hydrazino-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylate (17). A mixture of compound 15 (2.07 g; 5 mmol) and hydrazine hydrate 99% (1.0 mL, 20 mmol) in ethanol (20 mL) was heated at reflux for 2 h. The precipitate was collected and recrystallized from dioxane to give 17. Prepared as white crystals in 88% yield. mp 239-240 °C. IR (KBr) cm⁻¹: 3380, 3251 (NHNH₂), 2972 (C-H aliphatic), 1723 (C=O), 1659 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 9.04 (s, 1H, NH), 7.38 (s, 1H, CH pyrimidine), 6.93 -7.29 (m, 6H, NH₂ and Ar-H), 4.03-4.06 (q, 2H, OCH₂), 3.85 (s, 3H, OCH₃), 2.71 (s, 3H, CH₃), 0.98 -1.00 (t, 3H, CH₃ ester). Anal. Calcd. for C₂₀H₁₉N₅O₃S (409.1): C, 58.67; H, 4.68; N, 17.10; S, 7.83%. Found: C, 58.56; H, 4.43; N, 17.41; S, 7.62%.

Condensation of hydrazino compound 17 with 4-chlorobenzaldehyde or acetophenone; Formation of hydrazones 18 and 19 respectively. To a mixture of compound **17** (2.05 g; 5 mmol) and 4-chlorobenzaldehyde or acetophenone (5 mmol) in ethanol (20 mL), few drops of acetic acid were added. The reaction mixture was heated under reflux for 4 h. The solid that formed while hot was collected and recrystallized from DMF-H₂O mixture to give **18** and **19** respectively.

Ethyl 4-(4-chlorobenzylidenehydrazino)-9-(4-methoxyphenyl)-7-methyl-pyrido[3',2':4,5]thieno[3,2d]pyrimidine-8-carboxylate (18). Prepared as yellow crystals in 90% yield; mp 250-252 °C. IR (KBr) cm⁻¹: 3200 (NH), 2981 (C-H, aliphatic), 1722 (C=O), 1598 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 9.54 (br. s, 1H, NH), 8.45 (s, 1H, CH pyrimidine), 7.80 (s, 1H, N=CH), 7.74-7.76 (d, *J* 8.0 Hz, 2H, Ar-H), 7.43-7.45 (d, *J* 8.4 Hz, 2H, Ar-H), 7.36-7.38 (d, *J* 8.8 Hz, 2H, Ar-H), 6.98-7.00 (d, *J* 8.8 Hz, 2H, Ar-H), 4.08-4.13 (q, *J* 7.2 Hz, 2H, OCH₂), 3.89 (s, 3H, OCH₃), 2.78 (s, 3H, CH₃), 1.03-1.06 (t, *J* 7.0 Hz, 3H, CH₃ of ester); MS: *m/z* 531 (M⁺, 71%), 533 (M⁺-ClC₆H₄CH=N, 100%), 533 (M⁺+2, 27%), 365 (43%), 321 (30%). Anal. Calcd. for C₂₇H₂₂ClN₅O₃S (531.1): C, 60.96; H, 4.17; N, 13.16; S, 6.03%. Found: C, 60.78; H, 4.20; N, 13.00; S, 6.19%.

Acetophenone 8-ethoxycarbonyl-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-*d*]pyrimidin-4ylhydrazone (19). Prepared as yellow crystals in 88% yield; mp 225-226 °C. IR (KBr) cm⁻¹: 3186 (NH), 2974, 2926 (C-H, aliphatic), 1725 (C=O), 1610 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.648 (s, 1H, NH), 8.469 (s, 1H, CH pyrimidine), 7.95 (d, 2H, Ar-H), 7.25-7.51 (m, 5H, Ar-H), 6.98-700 (d, 2H, Ar-H), 4.07-4.12 (q, *J* 7.4 Hz, 2H, OCH₂), 3.90 (s, 3H, OCH₃), 2.78 (s, 3H, CH₃), 2.36 (s, 3H, CH₃ hydrazone), 1.02-1.06 (t, *J* 7.4 Hz, 3H, CH₃ ester); MS: *m/z* 511 (M⁺, 14%) 77 (C₆H₅⁺, 100%). Anal. Calcd. for C₂₈H₂₅N₅O₃S (511.1): C, 65.74; H, 4.93; N, 13.69; S, 6.27%. Found: C, 65.52; H, 4.70; N, 13.83; S, 6.02%.

Ethyl 4-(3,5-dimethyl-1-pyrazolyl)-9-(4-methoxyphenyl)-7-methylpyrido[3',2':4,5]thieno[3,2-d]pyrimidine-8carboxylate (20). A mixture of **17** (2.05 g; 5 mmol) and acetylacetone (15 mL) was gently heated at reflux for 4 h. The reaction mixture was triturated with ethanol (15 mL) and then left to cool. The precipitated product was collected and recrystallized from ethanol to give **20**. Obtained as white crystals in 77% yield; mp 146-147 °C. IR (KBr) cm⁻¹: 2977, 2838 (C-H, aliphatic), 1726 (C=O), 1610 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.73 (s, 1H, CH pyrimidine), 7.36-7.38 (d, *J* 8.8 Hz, 2H, Ar-H), 6.99-7.01 (d, *J* 8.4 Hz, 2H, Ar-H), 6.09 (s, 1H, CH pyrazole), 4.076-4.129 (q, *J* 7.0 Hz, 2H, OCH₂), 3.91 (s, 3H, OCH₃), 2.78 (s, 3H, CH₃), 2.77 (s, 3H, CH₃ pyrazole), 2.38 (s, 3H, CH₃ pyrazole), 1.02-1.06 (t, *J* 7.2 Hz, 3H, CH₃ ester); MS: *m/z* 473 (M⁺, 100%), 444 (M⁺-Et, 25%), 428 (M⁺-OEt, 11%), 400 (M⁺-CO₂Et, 10%). Anal. Calcd. for C₂₅H₂₃N₅O₃S (473.1): C, 63.41; H, 4.90; N, 14.79; S, 6.77%. Found: C, 63.09; H, 4.88; N, 14.70; S, 8.10%. **Ethyl 4-(5-amino-4-ethoxycarbonyl-1-pyrazolyl)-9-(4-methoxyphenyl)-7-methylpyrido**[3',2':4,5]thieno[3,2*d*]pyrimidine-8-carboxylate (21). A mixture of 17 (2.05 g; 5 mmol) and Ethyl (ethoxymethylene) cyanoacetate (0.85g; 5 mmol) in ethanol was heated at reflux for 4 h and then left to cool. The precipitated product was collected and recrystallized from ethanol to give 21. Obtained as white crystals in 80% yield; mp 193-194 °C. IR (KBr) cm⁻¹: 3416, 3300 (NH₂), 2981, 2934, 2839 (C-H, aliphatic), 1720 (C=O, ester), 1689 (C=O, ester group attached to pyrazole ring), 1626 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.73 (s, 1H, CH pyrimidine), 7.99 (s, 1H, CH pyrazole), 7.65 (br. s, 2H, NH₂), 7.35-7.37 (dd, 1.8 Hz, 2H, Ar-H), 6.99-7.01 (dd, 1.6 Hz, 2H, Ar-H), 4.29-4.35 (q, *J* 7.0 Hz, 2H, OCH₂), 4.07-4.13 (q, *J* 7.0 Hz, 2H, OCH₂), 3.91 (s, 3H, OCH₃), 2.77 (s, 3H, CH₃), 1.36-1.39 (t, *J* 7.0 Hz, 3H, CH₃ ester), 1.02-1.06 (t, *J* 7.0 Hz, 3H, CH₃ ester); MS: *m/z* 532 (M⁺, 100%), 485 (21%), 457 (15%). Anal. Calcd. for C₂₆H₂₄N₆O₅S (532.1): C, 58.64; H, 4.54; N, 15.78; S, 6.02%. Found: C, 58.43; H, 4.70; N, 15.83; S, 6.00%.

Ethyl 7-(4-methoxyphenyl-9-methyl[1,2,4]triazolo[4",3"-c]pyrido[3',2':4,5]thieno[2,3-c]pyrimidine-8carboxylate (23). Compound 17 (2.05 g; 5 mmol) in triethyl orthoformate (15 mL) was heated at reflux for 4 h. The precipitate that formed while hot was collected and recrystallized from ethanol to afford 23. Obtained as white crystals in 76% yield; mp 228-229 °C. IR (KBr) cm⁻¹: 3103 (C-H, aromatic), 1723 (C=O, ester), 1609 (C=N); ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.94 (s, 1H, CH pyrimidine), 8.76 (s, 1H, CH triazole), 7.31-7.34 (dd, J 2.4 Hz, 2H, Ar-H), 6.98-7.00 (dd, J 2.2 Hz, 2H, Ar-H), 4.09-4.14 (q, J 7.2 Hz, 2H, OCH₂), 3.90 (s, 3H, OCH₃), 2.77 (s, 3H, CH₃), 1.03-1.06 (t, J 7.2 Hz, 3H, CH₃ ester). Anal. Calcd. for C₂₁H₁₇N₅O₃S (419.1): C, 60.13; H, 4.09; N, 16.70; S, 7.64%. Found: C, 60.24; H, 4.32; N, 16.58; S, 7.60%.

Conclusions

Ethyl 3-amino-9-aryl-3,4-dihydro-4-imino-7-methylpyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylates **7a,b** and ethyl 4-chloro-9-(4-methoxy-phenyl)-7-methyl-pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-8-carboxylate (**17**) were synthesized and used as keys intermediate for synthesizing the promising pyridothienopyrimidines as well as triazolopyridothienopyrimidines and pyridothienopyrimidotriazinoindoles.

Acknowledgements

The authors are grateful to Prof. Y. Yamada, professor of chemistry, Faculty of Education, Utsunomiya University, Mine, Utsunomiya 321-8505, Japan for his help in carrying out the NMR and mass spectra of the compounds.

References

- Bakhite, E.A. Phosphorus Sulfur Silicon Relat. Elem. 2003, 178, 929.

 https://doi.org/10.1080/10426500307855
- 2. Litvinov, V.P.; Dotsenko, V.V.; Krivokolysko, S.G. Russ. Chem. Bull. Intern. Ed. 2005, 54, 864.

- Schnute, M.E.; Anderson, D.J.; Brideau, R.J.; Ciske, F.L.; Collier, S.A.; Cudahy, M.M.; Eggen, M.; Genin, M.J.; Hopkins, T.A.; Judge, T.M.; Kim, E.J.; Knechtel, M.L.; Nair, S.K.; Nieman, J.A. Oien, N.L.; Scott, A.; Tanis, S.P.; Vaillancount, V.A.; Wathen, M.W.; Wieber, J.L. *Bioorg. Med. Chem. Lett.* 2007, *17*, 3349. https://doi.org/10.1016/j.bmcl.2007.03.102
- 4. Attaby, F.A.; Elghandour, A.H.H.; Ali, M.A.; Ibrahem, Y.M. *Phosphorus Sulfur Silicon Relat. Elem.* 2007, 182, 695.

https://doi.org/10.1080/10426500601087277

- Bahekar, R.H.; Jain, M.R.; Jadav, P.A.; Prajapati, V.M.; Patel, D.N.; Gupta, A.A.; Sharma, A.; Tom, R.; Bandyopadhya, D.; Modi, H.; Patel, P.R. *Bioorg. Med. Chem.* 2007, 15, 6782. <u>https://doi.org/10.1016/j.bmc.2007.08.005</u>
- 6. Abdel-Rahman, A.E.; Bakhite, E.A.; Al-Taifi, E.A. *Pharmazie* **2003**, *58*, 372.
- 7. Hussin, A.M.; Abu-Shanab, F.A.; Ishak, E.A. *Phosphorus Sulfur Silicon Relat. Elem.* **2000**, *159*, 55. <u>https://doi.org/10.1080/10426500008043650</u>
- 8. Sohda, T.; Makino, H.; Baba, A. PCT Int. Appl. WO, **2006**, *96*, 14, 319.
- 9. Hayakawa, I.; Shioya, R.; Agatsuma, T.; Furukawa, H.; Sugano, Y. Bioorg. Med. Chem. Lett. 2004, 14, 3411.

https://doi.org/10.1016/j.bmcl.2004.04.079

- Bernardino, A.M.R.; Pinheiro, L.C.daS.; Rodrigues, C.R.; Loureiro, N.I.; Castro, H.C.; Lanfredi-Rangel, A.; Sabtini-Lopes, J.; Borges, J.C.; Carvalho, J.M.; Romeiro, G.A.; Ferreira, V.F.; Fruguphetti, I.C.P.P.; Vannier-Santos, M.A. *Bioorg. Med. Chem.* 2006, 14, 5765.
- 11. Krauze, A.; Germame, S; Eberlins, O.; Sturms, I.; Klusa, V.; Duburs, G. *Eur. J. Med. Chem.* **1999**, *34*, 301. https://doi.org/10.1016/S0223-5234(99)80081-6
- 12. Ibrahim, Y.A.; Elwahy, A.H.M.; Kadry, A.M. *Adv. Heterocyclic Chem.* **1996**, *65*, 235. <u>https://doi.org/10.1016/S0065-2725(08)60297-4</u>
- 13. Litvinov, V.P. Russ. Chem. Bull. Intern. Ed. 2004, 53, 487.
- Quintela, J.M.; Peinador, C.; Veiga, C.; Gonzales, L.; Botana, L.M.; Alfonso, A.; Riguera, R. *Bioorg. Med. Chem.* 1998, *6*, 1911. https://doi.org/10.1016/S0968-0896(98)00150-3
- Quintela, J.M.; Peinador, C.; Gonzales, L.; Iglesias, R.; Parama, A.; Alvares, F.; Sanmartin, M.L.; Riguera, R. *Eur. J. Med. Chem.* 2003, *38*, 265. https://doi.org/10.1016/S0223-5234(03)00032-1
- 16. Wagner, G.; Leistner, S.; Vieweg, H.; Krasselt, U.; Prantz, J. *Pharmazie* **1993**, *48*, 342.
- 17. Boehm, N.; Krasselt, U.; Leistner, S.; Wagner, G. *Pharmazie* **1992**, 47. 897.
- 18. Al-Taifi, E.A.; Thabet, E.A.; Bakhite, E.A.; El-Emary, T.I. AshEse J. Phys. Sci. 2016, 2, 033.
- 19. Bakhite, E.A.; Abeed, A.A.O.; Ahmed, O.E.A. *A.U.J.C.* **2016**, *45*, 47
- 20. Bakhite, E.A.; Abdel-Rahman, A.E.; Al-Taifi, E.A. *Arab. J. Chem.* **2014**, *7*, 936. <u>https://doi.org/10.1016/j.arabjc.2014.05.035</u>
- 21. Bakhite, EA; Al-Sehemi, A.G.; Yamada, Y. *J. Heterocyclic Chem.* **2005**, *42*, 1069. <u>https://doi.org/10.1002/jhet.5570420606</u>
- 22. Wagner, G.; Krasselt, U.; Leistner, S. *Pharamazie* **1991**, *46*, 409.
- 23. Allen, C.F.H.; Beilfuss, H.R.; Burness, D.M.; Reynolds, G.A.; Tinker, J.F.; Van Allan, J.A. *J. Org. Chem.* **1959**, 24, 787.

https://doi.org/10.1021/jo01088a014

- 24. Gad El-Kareem, M.A.M.; Abdel-Fattah, A.M. *Phosphorus Sulfur Silicon Relat. Elem.* **2006**, *181*, 891. https://doi.org/10.1080/10426500500272152
- 25. Gad El-Kareem, M.A.M.; El-Adasy, A.A.A.M. *Phosphorus Sulfur Silicon Relat. Elem.* **2010**, *185*, 411. https://doi.org/10.1080/10426500902800253